Last reviewed · How we verify
Trissodium Citrate 30%
Trisodium citrate acts as an anticoagulant by chelating calcium ions, thereby inhibiting the coagulation cascade and preventing blood clot formation.
Trisodium citrate acts as an anticoagulant by chelating calcium ions, thereby inhibiting the coagulation cascade and preventing blood clot formation. Used for Anticoagulant for blood collection and laboratory testing, Anticoagulant for extracorporeal circulation and dialysis.
At a glance
| Generic name | Trissodium Citrate 30% |
|---|---|
| Also known as | CitraLock(Trade Mark) |
| Sponsor | University of Sao Paulo |
| Drug class | Anticoagulant |
| Target | Ionized calcium (Ca2+) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Trisodium citrate binds ionized calcium (Ca2+) in blood, reducing the concentration of free calcium required for multiple steps of the coagulation cascade. By lowering available calcium, it prevents the activation of clotting factors and thrombin generation. This mechanism makes it useful as an anticoagulant in blood collection tubes and extracorporeal circuits.
Approved indications
- Anticoagulant for blood collection and laboratory testing
- Anticoagulant for extracorporeal circulation and dialysis
Common side effects
- Hypocalcemia (if administered systemically)
- Citrate toxicity (metabolic alkalosis, hypernatremia)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trissodium Citrate 30% CI brief — competitive landscape report
- Trissodium Citrate 30% updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI